- Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL).
- The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR and rituximab maintenance.
- Median progression-free survival (PFS) was 80.6 months with ibrutinib combined with bendamustine-rituximab and rituximab maintenance.
- That compared with 52.9 months for the chemotherapy regimen in the 523-patient trial.
- MCL is a rare type of lymphoma with an incidence of around 1 case per 200,000 people a year.
- The complete response rate was 65.5% in the ibrutinib group and 57.6% in the placebo.
- There was no difference in overall survival (OS) between treatment groups. The patients in the study continue to be followed for longer-term OS.
- Price Action: JNJ shares are up 0.65% at $177.57, and ABBV shares are down 0.36% at $146.64 during the market session on the last check Monday.
